학술논문
Bimekizumab for the Treatment of Plaque Psoriasis with Involvement of Genitalia: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis).
Document Type
Academic Journal
Author
Orsini D; Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.; Malagoli P; Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.; Balato A; Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.; Bianchi L; Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Brianti P; Unit of Dermatology and Cosmetology, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Buononato D; Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy.; Burlando M; Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.; Caldarola G; Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.; Dermatology Unit, Agostino Gemelli University Polyclinic Foundation, IRCCS, Rome, Italy.; Campanati A; Department of Clinical and Molecular Sciences - Dermatological Clinic, Università Politecnica delle Marche, Ancona, Italy.; Campione E; Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Carrera CG; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Carugno A; Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.; Molecular and Translational Medicine (DIMET), University of Milan-Bicocca, Milan, Italy.; Cusano F; Department of Dermatology, Gaetano Rummo Hospital, Benevento, Italy.; Dapavo P; Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.; Dattola A; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.; De Simone C; Section of Dermatology, Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Rome, Italy.; Dermatology Unit, Agostino Gemelli University Polyclinic Foundation, IRCCS, Rome, Italy.; Dini V; Dermatology Unit, Department of Clinical and Experimental Medicine, Ospedale Santa Chiara, Pisa, Italy.; Esposito M; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; Fargnoli MC; Dermatology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; Gaiani FM; Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy.; Gargiulo L; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Gisondi P; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.; Giunta A; Dermatology, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.; Ibba L; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; Lasagni C; Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy.; Loconsole F; Department of Dermatology, University of Bari, Bari, Italy.; Maione V; Department of Dermatology, ASST Spedali Civili Hospital, Brescia, Italy.; Mortato E; Department of Dermatology, University of Bari, Bari, Italy.; Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.; Maurelli M; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.; Megna M; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Mercuri SR; Università Vita-Salute San Raffaele, Milan, Italy.; Unit of Dermatology and Cosmetology, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Narcisi A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Offidani A; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.; Paolino G; Unit of Dermatology and Cosmetology, IRCCS San Raffaele Scientific Institute, Milan, Italy.; Parodi A; Section of Dermatology, Department of Health Sciences (DISSAL), IRCCS San Martino University Hospital, Genoa, Italy.; Pellacani G; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.; Potestio L; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Quaglino P; Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.; Richetta AG; Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.; Romano F; Dermatology Unit, AORN 'A. Cardarelli', Naples, Italy.; Sena P; Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.; Venturini M; Department of Dermatology, ASST Spedali Civili Hospital, Brescia, Italy.; Assorgi C; Clinical Dermatology Unit, San Gallicano Dermatological Institute IRCCS, Rome, Italy.; Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.; Costanzo A; Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Source
Publisher: International Dermoscopy Society Country of Publication: Austria NLM ID: 101585990 Publication Model: Electronic Cited Medium: Print ISSN: 2160-9381 (Print) Linking ISSN: 21609381 NLM ISO Abbreviation: Dermatol Pract Concept Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
2160-9381
Abstract
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis.
Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia.
Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index.
Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g = 0) within 16 weeks. Moreover, consistent improvements were observed in Psoriasis Area and Severity Index scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index, signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity.
Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.
Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia.
Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index.
Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g = 0) within 16 weeks. Moreover, consistent improvements were observed in Psoriasis Area and Severity Index scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index, signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity.
Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.